Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IV, Open Label Study of the Effects of Apremilast on Vascular Inflammation and Cardiometabolic Function in Psoriasis

Trial Profile

A Phase IV, Open Label Study of the Effects of Apremilast on Vascular Inflammation and Cardiometabolic Function in Psoriasis

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 30 Nov 2018

At a glance

  • Drugs Apremilast (Primary)
  • Indications Cardiovascular disorders; Plaque psoriasis
  • Focus Therapeutic Use
  • Acronyms VIP-A
  • Most Recent Events

    • 26 Nov 2018 Planned End Date changed from 1 Jan 2020 to 1 Jan 2021.
    • 26 Nov 2018 Planned primary completion date changed from 1 Mar 2019 to 1 May 2020.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top